IntelGenx president and CEO Horst Zerbe said that physicians would embrace CPI-300 as a safe alternative for patients requiring high-dose anti-depressant therapy.
”So we now turn our focus towards the commercialisation of CPI-300, with the objective of a product launch with a partner by the second quarter of 2012," Zerbe added.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact
Excellence in Action Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..
